We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “In this final follow-up from the SIMPLICITY HTN-3 trial ...

Please provide your email address to receive an email when new articles are posted on . Radiofrequency renal denervation is estimated to be a cost-effective treatment for uncontrolled hypertension.

Medtronic and Recor Medical stand to benefit from national Medicare coverage for their new device-based treatments for patients with uncontrolled high blood pressure. Medtronic and Recor have had ...

A radiofrequency-based renal denervation system for uncontrolled hypertension got a cool reception from FDA advisors who nevertheless left the door open for regulatory approval. On Wednesday, the ...

Renal denervation using radiofrequency energy is a cost-effective and high-value intervention for the treatment of uncontrolled hypertension from the perspective of the US healthcare system, an ...

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term ...

Catheter-based, radiofrequency renal denervation is a cost-effective solution for patients with hypertension, according to a study published Aug. 13 in the Journal of the Society for Cardiovascular ...

Renal denervation delivers radiofrequency energy to overactive nerves in renal arteries and branch vessels. Renal denervation along with use of antihypertensive drugs leads to a sustained reduction in ...

Kidney denervation, a procedure where the nerves in renal arteries are burned, may be a future treatment for people whose blood pressure remains high despite medication use. Results from the ...

PARIS, France—Patients who spend the most time with optimally controlled blood pressure after renal denervation have a lower rate of major cardiovascular events than do those with less-than-ideal ...

The US Food and Drug Administration (FDA) is expected to have data next year that could lead to approval of a renal denervation device to lower blood pressure—but will the data be strong enough to ...